Parkinson's disease and pain: Modulation of nociceptive circuitry in a rat model of nigrostriatal lesion

Imagem de Miniatura
Arquivos
art_DOMENICI_Parkinsons_disease_and_pain_Modulation_of_nociceptive_circuitry_2019.PDF (2.4 MB)
Citações na Scopus
38
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ACADEMIC PRESS INC ELSEVIER SCIENCE
Autores
DOMENICI, Roberta A.
CAMPOS, Aria Carolina P.
MACIEL, Soraya T.
BERZUINO, Miria B.
HERNANDES, Marina S.
PAGANO, Rosana L.
Citação
EXPERIMENTAL NEUROLOGY, v.315, p.72-81, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Parkinson's disease (PD) is a neurodegenerative disorder that causes progressive dysfunction of dopaminergic and non-dopaminergic neurons, generating motor and nonmotor signs and symptoms. Pain is reported as the most bothersome nonmotor symptom in PD; however, pain remains overlooked and poorly understood. In this study, we evaluated the nociceptive behavior and the descending analgesia circuitry in a rat model of PD. Three independent experiments were performed to investigate: i) thermal nociceptive behavior; ii) mechanical nociceptive behavior and dopaminergic repositioning; and iii) modulation of the pain control circuitry. The rat model of PD, induced by unilateral striatal 6-hydroxydopamine (6-OHDA), did not interfere with thermal nociceptive responses; however, the mechanical nociceptive threshold was decreased bilaterally compared to that of naive or striatal saline-injected rats. This response was reversed by apomorphine or levodopa treatment. Striatal 6-OHDA induced motor impairments and reduced dopaminergic neuron immunolabeling as well as the pattern of neuronal activation (c-Fos) in the substantia nigra ipsilateral (IPL) to the lesion. In the midbrain periaqueductal gray (PAG), 6-OHDA-induced lesion increased IPL and decreased contralateral PAG GABAergic labeling compared to control. In the dorsal horn of the spinal cord, lesioned rats showed bilateral inhibition of enkephalin and p-opioid receptor labeling. Taken together, we demonstrated that the unilateral 6-OHDA-induced PD model induces bilateral mechanical hypernociception, which is reversed by dopamine restoration, changes in the PAG circuitry, and inhibition of spinal opioidergic regulation, probably due to impaired descending analgesic control. A better understanding of pain mechanisms in PD patients is critical for developing better therapeutic strategies to improve their quality of life.
Palavras-chave
Dopaminergic agonists, Enkephalin, GABA, Pain, Parkinson's disease, Perlaqueductal gray, Spinal cord
URI
https://observatorio.fm.usp.br/handle/OPI/31740
Referências
  1. AGID Y, 1991, LANCET, V337, P1321, DOI 10.1016/0140-6736(91)92989-F
  2. ANGLADE P, 1995, ANN NEUROL, V37, P265, DOI 10.1002/ana.410370219
  3. Bannister K, 2016, CURR OPIN SUPPORT PA, V10, P143, DOI 10.1097/SPC.0000000000000207
  4. Barneoud P, 2000, EUR J NEUROSCI, V12, P322, DOI 10.1046/j.1460-9568.2000.00896.x
  5. BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521
  6. Beiske AG, 2009, PAIN, V141, P173, DOI 10.1016/j.pain.2008.12.004
  7. Bianchi L, 2003, EUR J NEUROSCI, V18, P856, DOI 10.1046/j.1460-9568.2003.02795.x
  8. Blanchet PJ, 2018, PROG NEURO-PSYCHOPH, V87, P200, DOI 10.1016/j.pnpbp.2017.10.010
  9. Blandini Fabio, 2008, Parkinsonism Relat Disord, V14 Suppl 2, pS124, DOI 10.1016/j.parkreldis.2008.04.015
  10. Blaszczyk JW, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00269
  11. Brefel-Courbon C, 2005, MOVEMENT DISORD, V20, P1557, DOI 10.1002/mds.20629
  12. Broadhurst P. L., 1960, HDB ABNORMAL PSYCHOL, P726
  13. Budai D, 1998, J NEUROPHYSIOL, V79, P677
  14. Cao LF, 2016, NEURAL PLAST, DOI 10.1155/2016/6383240
  15. Carta M, 2007, BRAIN, V130, P1819, DOI 10.1093/brain/awm082
  16. CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
  17. Charles KA, 2018, MOVEMENT DISORD, V33, P1010, DOI 10.1002/mds.27377
  18. Chaudhuri KR, 2009, LANCET NEUROL, V8, P464, DOI 10.1016/S1474-4422(09)70068-7
  19. Chen CCV, 2013, NEUROBIOL DIS, V49, P99, DOI 10.1016/j.nbd.2012.07.020
  20. Chiou LC, 1999, J PHYSIOL-LONDON, V518, P551, DOI 10.1111/j.1469-7793.1999.0551p.x
  21. CHUDLER EH, 1995, PAIN, V60, P3, DOI 10.1016/0304-3959(94)00172-B
  22. Chudler EH, 2008, BRAIN RES, V1213, P41, DOI 10.1016/j.brainres.2008.03.053
  23. CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H
  24. D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74
  25. Delaville C, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00031
  26. Dellapina E, 2011, MOVEMENT DISORD, V26, P153, DOI 10.1002/mds.23406
  27. Deumens R, 2002, EXP NEUROL, V175, P303, DOI 10.1006/exnr.2002.7891
  28. di Michele F, 2013, FRONT NEUROENDOCRIN, V34, P132, DOI 10.1016/j.yfrne.2013.03.001
  29. Dieb W, 2014, BRAIN BEHAV, V4, P368, DOI 10.1002/brb3.214
  30. DOLPHIN A, 1976, PHARMACOL BIOCHEM BE, V5, P431, DOI 10.1016/0091-3057(76)90107-6
  31. Factor SA, 2000, MOVEMENT DISORD, V15, P167, DOI 10.1002/1531-8257(200001)15:1<167::AID-MDS1029>3.0.CO;2-8
  32. FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.ne.14.030191.001251
  33. FLORAN B, 1988, EUR J PHARMACOL, V150, P277, DOI 10.1016/0014-2999(88)90008-8
  34. Flores JA, 2004, PAIN, V110, P205, DOI 10.1016/j.pain.2004.03.036
  35. Gee LE, 2016, EXP NEUROL, V283, P298, DOI 10.1016/j.expneurol.2016.06.031
  36. Gerdelat-Mas A, 2007, J NEUROL NEUROSUR PS, V78, P1140, DOI 10.1136/jnnp.2007.120212
  37. Goetz C G, 1986, Mov Disord, V1, P45, DOI 10.1002/mds.870010106
  38. Gonzalez-Hernandez T, 2000, J COMP NEUROL, V421, P107, DOI 10.1002/(SICI)1096-9861(20000522)421:1<107::AID-CNE7>3.0.CO;2-F
  39. Guo D, 2014, NEUROSCIENCE, V283, P95, DOI 10.1016/j.neuroscience.2014.09.032
  40. Hagelberg N, 2002, PAIN, V99, P273, DOI 10.1016/S0304-3959(02)00121-5
  41. Hahm ET, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-41
  42. HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7
  43. Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6
  44. Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6
  45. HOKFELT T, 1973, BRAIN RES, V60, P269, DOI 10.1016/0006-8993(73)90791-9
  46. Hornykiewicz O, 1987, Adv Neurol, V45, P19
  47. Jackson-Lewis Vernice, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS183, DOI 10.1016/S1353-8020(11)70057-8
  48. Jaskiw GE, 2004, PSYCHOPHARMACOLOGY, V171, P365, DOI 10.1007/s00213-003-1672-y
  49. JOHNSON RE, 1993, MED CARE, V31, P432, DOI 10.1097/00005650-199305000-00005
  50. Kalyuzhny AE, 1998, J COMP NEUROL, V392, P528
  51. Kaszuba BC, 2017, BRAIN RES, V1655, P233, DOI 10.1016/j.brainres.2016.10.025
  52. Kemp T, 1996, NEUROSCIENCE, V75, P1231, DOI 10.1016/0306-4522(96)00333-8
  53. Kim J. Y, 2014, J NEUROSCI, V22, P6307, DOI [10.1523/jneurosc.3481-14,2015, DOI 10.1523/JNEUROSC.3481-14.2015]
  54. Kirik D, 1998, EXP NEUROL, V152, P259, DOI 10.1006/exnr.1998.6848
  55. Lau BK, 2014, CURR OPIN NEUROBIOL, V29, P159, DOI 10.1016/j.conb.2014.07.010
  56. Magnusson JE, 2000, BRAIN RES, V855, P260, DOI 10.1016/S0006-8993(99)02396-3
  57. Marker CL, 2006, J NEUROSCI, V26, P12251, DOI 10.1523/JNEUROSCI.3693-06.2006
  58. MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
  59. Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
  60. Milligan ED, 2003, J NEUROSCI, V23, P1026
  61. MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112
  62. Nandhagopal R, 2010, PAIN MED, V11, P834, DOI 10.1111/j.1526-4637.2010.00866.x
  63. Nascimento GC, 2018, NEUROTOX RES, V34, P799, DOI 10.1007/s12640-018-9896-0
  64. Obese J. A, 2000, NEUROLOGY, V55
  65. Obeso JA, 2004, NEUROLOGY, V62, pS17, DOI 10.1212/WNL.62.1_suppl_1.S17
  66. Obeso JA, 2000, NEUROLOGY, V55, pS13
  67. Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766
  68. Pagano RL, 2012, PAIN, V153, P2359, DOI 10.1016/j.pain.2012.08.002
  69. Paxinos G., 2005, RAT BRAIN STEREOTAXI
  70. Pertovaara A, 2006, PROG NEUROBIOL, V80, P53, DOI 10.1016/j.pneurobio.2006.08.001
  71. Pertovaara A, 2006, HAND CLINIC, V81, P179, DOI 10.1016/S0072-9752(06)80017-5
  72. Polgar E, 2003, PAIN, V104, P229, DOI 10.1016/S0304-3959(03)00011-3
  73. PRZEDBORSKI S, 1995, NEUROSCIENCE, V67, P631, DOI 10.1016/0306-4522(95)00066-R
  74. Quittenbam BH, 2004, PARKINSONISM RELAT D, V10, P129, DOI 10.1016/j.parkreldis.2003.12.001
  75. Rana AQ, 2013, CLIN NEUROL NEUROSUR, V115, P2313, DOI 10.1016/j.clineuro.2013.08.022
  76. RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409
  77. Rangel-Barajas C, 2008, NEUROPHARMACOLOGY, V55, P704, DOI 10.1016/j.neuropharm.2008.06.002
  78. RAYNOR K, 1994, MOL PHARMACOL, V45, P330
  79. RUDA MA, 1986, PROG BRAIN RES, V66, P219, DOI 10.1016/S0079-6123(08)64606-3
  80. Saade NE, 1997, BRAIN RES, V751, P1, DOI 10.1016/S0006-8993(96)01164-X
  81. SANBERG PR, 1980, NATURE, V284, P472, DOI 10.1038/284472a0
  82. SCATTON B, 1983, BRAIN RES, V275, P321, DOI 10.1016/0006-8993(83)90993-9
  83. Sgroi S, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00524
  84. Somers DL, 2002, NEUROSCI LETT, V323, P171, DOI 10.1016/S0304-3940(02)00157-X
  85. Stefano GB, 2012, MED SCI MONITOR, V18, pRA133, DOI 10.12659/MSM.883259
  86. Takeda R, 2014, NEUROSCI LETT, V573, P19, DOI 10.1016/j.neulet.2014.05.007
  87. Taniguchi W, 2011, PAIN, V152, P95, DOI 10.1016/j.pain.2010.09.034
  88. Tassorelli C, 2007, BRAIN RES, V1176, P53, DOI 10.1016/j.brainres.2007.08.012
  89. Taylor AMW, 2016, PAIN, V157, P1194, DOI 10.1097/j.pain.0000000000000494
  90. Todd AJ, 2010, NAT REV NEUROSCI, V11, P823, DOI 10.1038/nrn2947
  91. Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012
  92. Vallone D, 2000, NEUROSCI BIOBEHAV R, V24, P125, DOI 10.1016/S0149-7634(99)00063-9
  93. Vanegas H, 2004, BRAIN RES REV, V46, P295, DOI 10.1016/j.brainresrev.2004.07
  94. Visser M, 2009, VALUE HEALTH, V12, P392, DOI 10.1111/j.1524-4733.2008.00430.x
  95. Wang B, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00120
  96. Wang CT, 2017, MOL PAIN, V13, DOI 10.1177/1744806917691525
  97. Wang Y, 2010, BRAIN RES, V1324, P54, DOI 10.1016/j.brainres.2010.02.008
  98. Wood Patrick B, 2008, Expert Rev Neurother, V8, P781, DOI 10.1586/14737175.8.5.781
  99. Zengin-Toktas Y, 2013, NEUROSCI RES, V76, P261, DOI 10.1016/j.neures.2013.05.003
  100. Zhang X, 2008, P NATL ACAD SCI USA, V105, P2163, DOI 10.1073/pnas.0711839105
  101. ZIGMOND MJ, 1984, ARCH NEUROL-CHICAGO, V41, P856, DOI 10.1001/archneur.1984.04050190062015
  102. ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4

Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/45